Global Dialysis - Akela Pharma signs an exclusive development agreement to develop special oral dosage forms at its PharmaForm subsidiary (CNW Group via Yahoo! Finance)

Akela Pharma signs an exclusive development agreement to develop special oral dosage forms at its PharmaForm subsidiary (CNW Group via Yahoo! Finance)

Akela Pharma Inc. , a drug development company focused on developing an inhaled fentanyl product for breakthrough cancer pain and a growth hormone releasing hormone for chronic renal disease, today announced that its wholly owned subsidiary, PharmaForm, has signed a development agreement with an undisclosed global pharmaceutical company, to develop specialized oral dosage forms at its facility ...